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A B S T R A C T
Background
Pneumonia is one of the most common, serious infections, causing two million deaths annually among young children in low-income
countries. In high-income countries pneumonia is most significantly a problem of the elderly.
Objectives
To assess the prophylactic and therapeutic effects of vitamin C on pneumonia.
Search methods
We searched the Cochrane Central Register of Controlled Trials (CENTRAL 2011, Issue 1) which contains the Acute Respiratory
Infections Group’s Specialised Register, MEDLINE (1950 to January week 4, 2011), EMBASE (1974 to February 2011) and Web of
Science (1945 to February 2011).
Selection criteria
To assess the therapeutic effects of vitamin C, we selected placebo-controlled trials. To assess prophylactic effects, we selected controlled
trials with or without a placebo.
Data collection and analysis
Two review authors independently read the trial reports and extracted data.
Main results
We identified three prophylactic trials which recorded 37 cases of pneumonia in 2335 people. Only one was satisfactorily randomised,
double-blind and placebo-controlled. Two trials examined military recruits and the third studied boys from “lower wage-earning classes”
attending a boarding school in the UK during World War II. Each of these trials found a statistically significant (80% or greater)
reduction in pneumonia incidence in the vitamin C group. We identified two therapeutic trials involving 197 pneumonia patients.
Only one was satisfactorily randomised, double-blind and placebo-controlled. That trial studied elderly patients in the UK and found
lower mortality and reduced respiratory symptom scores in the vitamin C group; however, the benefit was restricted to the most ill
patients. The other therapeutic trial studied adults with a wide age range in the former Soviet Union and found a dose-dependent
reduction in the time to recovery with two vitamin C doses.
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Authors’ conclusions
The prophylactic use of vitamin C to prevent pneumonia should be further investigated in populations who have high incidence of
pneumonia, especially if dietary vitamin C intake is low. Similarly, the therapeutic effects of vitamin C should be studied, especially
in patients with low plasma vitamin C levels. The current evidence is too weak to advocate widespread prophylactic use of vitamin C
to prevent pneumonia in the general population. However, therapeutic vitamin C supplementation may be reasonable for pneumonia
patients who have low vitamin C plasma levels because its cost and risks are low.
P L A I N L A N G U A G E S U M M A R Y
Vitamin C for preventing and treating pneumonia
Pneumonia is an infection of the lungs caused by bacteria, viruses or other infectious agents. Its clinical diagnosis is sometimes difficult.
Pneumonia is more common in young children and in the aged. In low-income countries it causes two million deaths annually among
young children. In the USA it is the most common cause of death from infection.
Vitamin C was identified in the early 1900s and suggestions that one of its biological roles may be to resist infections are supported
by numerous animal studies. We looked for studies in humans and found three trials with a total of 2335 participants that looked at
whether vitamin C prevents pneumonia. Two of the preventive trials studied soldiers while the third studied boys in a UK boarding
school in the 1940s. Two other trials with a total of 197 pneumonia patients looked at whether vitamin C might help to cure pneumonia.
One studied patients aged 66 to 94 years in the UK with pneumonia and benefit was restricted to those who were most ill and had low
vitamin C levels. The other trial was conducted in the former Soviet Union but the social and nutritional backgrounds of the patients
were not described. None of the five trials reported noteworthy adverse effects of vitamin C.
Overall, the results of the five identified trials suggested vitamin C is beneficial in both preventing and treating pneumonia. However,
these trials were carried out in such extraordinary conditions that the results may not apply to the general population. Therefore, more
research is needed. In the meantime, supplementing pneumonia patients who have low plasma vitamin C levels may be reasonable
because of its safety and low cost.
B A C K G R O U N D
Description of the condition
Pneumonia is an infection of the lungs and can be caused by
bacteria, viruses, Rickettsia, fungi or parasites. Nearly 100 species
have been identified as aetiological agents (Donowitz 2005; File
2003; Ruuskanen 2011). Although the pathological definition of
pneumonia is clear, the clinical diagnosis is sometimes ambiguous.
The risk of pneumonia is increased in young children and the
elderly. In low-income countries, pneumonia causes two million
deaths annually among children under five years of age (Graham
1990; Jones 2003; Rudan 2004). In the USA, pneumonia is the
sixth most common cause of death and the most common cause
of infection-related death (Donowitz 2005).
Description of the intervention
Although vitamin C affects the immune system, it may only af-
fect particular conditions. For example, it is possible that variation
in vitamin C intake does not affect the immune system in the
ordinary Western population because of their relatively high di-
etary intake levels. Vitamin C might, however, be a limiting factor
in populations with low intakes. An extreme example is the high
prevalence of frank vitamin C deficiency, apparent as scurvy, in
refugee camps in the Horn of Africa; reported to be up to 44%
(WHO 1999a). Vitamin C metabolism is affected in various in-
fections, including pneumonia, as indicated by decreased levels
in plasma, leucocytes and urine (Hemilä 1997a; Hemilä 1999;
Hemilä 2006a). These changes in metabolism mean that vitamin
C might have a treatment effect on pneumonia irrespective of di-
etary intake. In animal studies, vitamin C increased resistance to
various viral and bacterial infections (Hemilä 2006a).
In the early 1900s, Alfred Hess carried out extensive studies of
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scurvy and summarised a large series of autopsy findings: “pneu-
monia, lobular or lobar, is one of the most frequent complica-
tions [of scurvy] and causes of death” and “secondary pneumonias,
usually broncho-pneumonic in type, are of common occurrence,
and in many [scurvy] epidemics constitute the prevailing cause of
death” (Hess 1920). He further commented, in a major medical
journal a decade later, that in “infantile scurvy . . . a lack of the
antiscorbutic factor [vitamin C] which leads to scurvy, at the same
time predisposes to infections [particularly of the respiratory tract]
. . . Similar susceptibility to infections goes hand in hand with
adult scurvy” (Hess 1932). In the early 1900s, Casimir Funk, who
coined the term ’vitamin’, pointed out that an epidemic of pneu-
monia in the Sudan disappeared when antiscorbutic (vitamin C-
containing) treatment was given to the numerous cases of scurvy
which appeared at about the same time (Robertson 1934).
Since the 1930s, a few German and US physicians have proposed
that vitamin C might be beneficial in the treatment of pneumonia
(Bohnholtzer 1937; Hemilä 1999; Hochwald 1937). Gander and
Niederberger concluded from a series of 15 cases that “the general
condition is always favourably influenced [by vitamin C] to a
noticeable extent, as is the convalescence, which proceeds better
and more quickly than in cases of pneumonia which are not treated
with vitamin C” (Gander 1936). Benefit from intravenous vitamin
C was reported in a series of over 40 cases (Klenner 1948; Klenner
1951) and in three cases of viral pneumonia (Dalton 1962). A
large dose of oral vitamin C was also claimed to be beneficial in
patients with viral pneumonia (Cathcart 1981; Luberoff 1978).
The effect of vitamin C on the common cold has been studied ex-
tensively. A major finding from the trials is the heterogeneity in its
effects. Although the largest trials found no effect on common cold
incidence, the incidence was reduced in trials with participants
under heavy acute physical stress and in British males, which was
explained as the result of a diet low in vitamin C (Hemilä 1996;
Hemilä 1997b; Hemilä 2006a; Hemilä 2010). Consequently, it is
possible that the effects of vitamin C on other respiratory infec-
tions are also modified by various factors, such as physical stress
and dietary vitamin C intake. Also, two large trials found consid-
erable divergence in the effects of vitamin C depending on the type
of cold. Vitamin C decreased the incidence of ’chest colds’ (-18%;
cough or other chest symptoms) but not of ’simple colds’ (+1%;
runny nose or sneezing) (Elwood 1976; Hemilä 1997b). Similarly,
vitamin C decreased the incidence of ’throat colds’ (-21%) but not
’nose colds’ (-2%) (Anderson 1973; Hemilä 1997b). These two
trials thus suggest that vitamin C might have a greater effect on
infections affecting the lower respiratory tract.
In close parallel with vitamin C, lipid-soluble vitamin E is inter-
esting as these two antioxidants interact; vitamin C reduces ox-
idised vitamin E levels (Hamilton 2000; Hemilä 2006a; Packer
1979). In a large-scale trial the effect of vitamin E on the risk of
pneumonia was modified by the age at which participants began
smoking, such that vitamin E reduced the risk in those who began
smoking at a later age but increased the risk in those who began
smoking at an early age (Hemilä 2004). Vitamin E reduced the
risk of pneumonia by 50% in participants who exercised, also sug-
gesting heterogeneous effects between population groups (Hemilä
2006a; Hemilä 2006b). Even though direct extrapolation of find-
ings from vitamin E studies to vitamin C are unjustified, the no-
tion that various factors may modify the effects of antioxidants is
fundamentally important in restricting broad generalisations from
individual trials, irrespective of whether the finding is positive or
negative and whether or not the trial is large and carefully con-
ducted.
How the intervention might work
The major role of vitamin C in the immune system seems to be as
a physiological antioxidant, protecting host cells against oxidative
stress caused by infections. Its concentration in phagocytes and
lymphocytes is very high. In various experimental settings vitamin
C increased the functioning of phagocytes, the proliferation of
T-lymphocytes and the production of interferon; and decreased
replication of viruses (Beisel 1982; Hemilä 1997a; Hemilä 2003;
Thomas 1978; Webb 2007).
Approximately 10 mg/day of vitamin C prevents scurvy but the
safe dose range extends to grams per day. In the US nutritional
recommendations, the ’tolerable upper intake level’ is stated to be
2 g/day for adults. The basis for this upper limit is the appearance
of diarrhoea (IOM 2000) which is, however, a trivial adverse effect
that disappears quickly with a reduction in intake. Furthermore,
it has been stated that patients with pneumonia can take 100 g/
day of vitamin C without developing diarrhoea, possibly because
of the changes in vitamin C metabolism (Cathcart 1981).
Why it is important to do this review
Pneumonia is a fairly common and severe infection and vitamin
C is a safe and inexpensive essential nutrient. The possibility that
vitamin C might affect susceptibility to pneumonia, even in re-
stricted population groups, is worthy of examination. Similarly,
the possibility that vitamin C treatment might affect the duration
or severity of pneumonia, or both, is worthy of systematic consid-
eration. One previous meta-analysis assessed the preventive effects
of vitamin C on pneumonia (Hemilä 1997c) but the therapeutic
effect on pneumonia has not so far been assessed systematically.
Links to the publications cited in this section, for which full-text
versions are available, can be found at www.ltdk.helsinki.fi/users/
hemila/CP/.
O B J E C T I V E S
To analyse evidence regarding the effect of vitamin C supplemen-
tation on preventing and treating pneumonia.
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M E T H O D S
Criteria for considering studies for this review
Types of studies
For preventive trials of vitamin C supplementation we used con-
trolled trials. The use of placebo was not required as it seems un-
likely that being aware or not of taking vitamin C would affect
the occurrence of a severe infection. Also, since a recent meta-
analysis of trials comparing a placebo group with a no treatment
group found no evidence of a placebo effect on binary outcomes
(Hrobjartsson 2001; Hrobjartsson 2010), there is no empirical
evidence indicating that the placebo effect might affect the occur-
rence of pneumonia.
For treatment trials of vitamin C on the severity and duration of
pneumonia we used placebo-controlled trials since the outcome
(for example, severity) may be affected by the awareness of the
treatment by the patients. Also, the recent meta-analysis of trials
comparing a placebo group with a no treatment group found evi-
dence of a placebo effect in trials focusing on pain (Hrobjartsson
2001; Hrobjartsson 2010). A placebo control may, therefore, be
crucial for the validity of treatment observations.
Types of participants
For prevention trials there was no age restriction in the partici-
pants.
For treatment trials we restricted trials to participants with pneu-
monia (both community-acquired and nosocomial pneumonia)
with no age restrictions.
Types of interventions
Administration of vitamin C (ascorbic acid or its salts) to one trial
group, either orally or intravenously. There were no restrictions
on the dosage and frequency of administration of vitamin C and
treatment trials with a single dose were also included. We excluded
trials in which vitamin C was administered along with other sub-
stances, such as other vitamins.
Types of outcome measures
Primary outcomes
1. In assessing the preventive effect of vitamin C, the primary
outcome was the occurrence of pneumonia during vitamin C
supplementation.
2. In assessing the treatment effect of vitamin C, the primary
outcomes of interest were the duration and severity of
pneumonic episode, duration of hospital stay and death caused
by pneumonia.
For our review pneumonia was defined operationally as the dis-
ease that the original trial authors classified as pneumonia. The
basis of the diagnosis by the original authors is described in the
’Description of studies’ section. We did not require that the pneu-
monia diagnosis was based on chest X-radiography (CXR) but we
also accepted a clinical diagnosis of pneumonia (see Appendix 1
for details).
Secondary outcomes
We classified laboratory findings, such as C-reactive protein or ery-
throcyte sedimentation rate, as secondary outcomes. CXR changes
and body temperature changes during treatment are classified as
secondary outcomes.
Search methods for identification of studies
Electronic searches
For this 2011 update we searched the Cochrane Central Regis-
ter of Controlled Trials (CENTRAL 2011, Issue 1) which con-
tains the Acute Respiratory Infections Group’s Specialised Regis-
ter, MEDLINE (1950 to January week 4, 2011), EMBASE (1974
to February 2011) and Web of Science (1945 to February 2011).
Details of the previous search are in Appendix 2.
We searched CENTRAL and MEDLINE using the following
search strategy. We did not use a filter to identify randomised trials
as there were too few results. We adapted the search for EMBASE













13 6 and 12
Searching other resources
Previously, Briggs 1984 carried out extensive searches of the liter-
ature and published a bibliography containing 413 references to
papers related to vitamin C and infections. We perused the Briggs
bibliography and other pertinent reviews and publications along
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with the results of the database searches. Although our systematic
review is focused on controlled trials, we also collected observa-
tional studies and trials of vitamin mixtures containing vitamin
C. These were considered in the Discussion section if they were
pertinent to the review. There were no language restrictions in the
literature searches.
Data collection and analysis
Selection of studies
The contact author (HH) searched the literature and both review
authors (HH, PL) independently assessed the extracted titles and
abstracts to identify potentially relevant articles. We excluded trials
failing to meet the inclusion criteria. When we disagreed on the
relevance of an article, we discussed it until we reached a consensus.
Data extraction and management
Both review authors (HH, PL) independently extracted relevant
data from the articles selected. When we differed in the interpre-
tation of study findings we sought a consensus.
Assessment of risk of bias in included studies
We recorded the following quality features of the trials: alloca-
tion concealment, blinding, proportion of drop-outs and other
relevant features that may limit the validity of the trial. We did
not calculate any quality scores for the selected trials since “qual-
ity scores are at best useless and at worst misleading” (Greenland
1994). We agree with the Shapiro 1997 comment that quality is
best evaluated qualitatively. The Cochrane Handbook for Systematic
Reviews of Interventions also states that “The use of scales for as-
sessing quality or risk of bias is explicitly discouraged in Cochrane
reviews” (Higgins 2011).
Measures of treatment effect
We planned to calculate risk ratios (RR) for dichotomous out-
come variables. However, in the identified prophylactic trials the
number of pneumonia cases in the vitamin C groups was very
low (zero to two cases) and, therefore, we decided to use the Peto
method for calculating the odds ratio (OR), which does not need
corrections for zero cell counts (Higgins 2011). Also, with only a
few cases observed in the trial groups, the mid-P value is the most
appropriate method to calculate the P values for the differences in
the treatment groups (Hemilä 2006a) and was used when com-
paring groups with small numbers of cases. We used two-tailed P
values in this review.
Unit of analysis issues
The Glazebrook 1942 study reported the number of pneumonia
cases per seven administrative groups of the school. Thus, the unit
of analysis is the group of schoolchildren in the administrative
division. Glazebrook describes that “The youths of one division
worked as a unit, and occupied certain tables in the dining hall. To
some extent each division occupied particular dormitories, but this
separation was not absolute, and there was a fair amount of mixing
of divisions in the sleeping quarters. Sleeping and feeding condi-
tions were, of course, the same for all divisions. Careful records
had been kept of the incidence of all infections for 1½ years before
the observations described here were begun. In the preceding year
there had been an epidemic of tonsillitis, which had affected all the
divisions uniformly, so that they could not be regarded as separate
units within the larger population.” Therefore, we consider that
the schoolboys had a similar risk of pneumonia in each division
and we carried out our primary analysis by the vitamin C and
no vitamin C groups. However, as a sensitivity analysis, we also
analysed the data by administrative units (see Results).
Other studies included in our analyses do not have unit of analysis
concerns.
Dealing with missing data
None of the trials had missing data that we needed to impute.
Assessment of heterogeneity
We assessed the heterogeneity of a trial in the same analysis by
using the I2 statistic (Higgins 2003). This examines the percent-
age of total variation across studies that is due to heterogeneity
rather than chance. A value of I2 statistic greater than about 70%
indicates a high level of heterogeneity. We also used the Chi2 test
to calculate the probability that the observed heterogeneity was
caused by chance.
Assessment of reporting biases
We did not construct funnel plots as we do not consider them to
be a useful tool when deciding whether there is publication bias
or not (Ioannidis 2007; Lau 2006).
Data synthesis
We planned that if a number of trials were available with sufficient
uniformity in settings and outcome definitions, we would pool
the data; but, if the trials were heterogeneous, either statistically
or clinically, we would present them separately. There is no statis-
tical heterogeneity in Analysis 1.1 but the studies are clinically so
divergent that we considered pooling was inappropriate.
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Subgroup analysis and investigation of heterogeneity
We included both community-acquired and nosocomial pneumo-
nia in this review. However, due to their substantial clinical differ-
ences, we planned to analyse them separately. We did not identify
any trials on nosocomial pneumonia.
We did not use poor descriptions of the definition of pneumonia
as a basis to exclude a trial from the review. However, we planned
to carry out subgroup analyses based on the rigour of our outcome
definition (CXR or not) and on the level of blinding of outcome
assessments. Given the trials we identified, this did not differ from
the sensitivity analysis based on the methodological quality of the
trials.
We did not set limits on the vitamin C doses for the inclusion
of trials but we planned to carry out subgroup analyses based on
dosage. In the preventive trials, we decided to set the limit of
subgroup analysis to 100 mg/day, since it is close to the dosage
leading to maximum vitamin C plasma levels in healthy people. In
the treatment trials, we decided to set the limit of subgroup analysis
to 1000 mg/day, since there is evidence of changes in vitamin
C metabolism in infections and larger doses might, therefore, be
needed for significant effects. We did not find suitable variation in
the doses that would make subgroup analysis by dose reasonable,
except in the within-study variation in the Mochalkin 1970 trial
(Table 1).
Sensitivity analysis
Two of the identified trials were double-blind, placebo-con-
trolled, randomised controlled trials (RCTs) (Hunt 1994; Pitt
1979) whereas three studies were methodologically less satisfac-
tory (Glazebrook 1942; Kimbarowski 1967; Mochalkin 1970).
We carried out sensitivity analysis by excluding the latter three
methodologically poorer quality trials.
Glazebrook 1942 had a unit of observation of an administrative
group in a boarding school. We analysed their data assuming a
similar risk for each participant in each administrative unit, but as a
sensitivity analysis we also analysed their data by the administrative
groups.
R E S U L T S
Description of studies
See: Characteristics of included studies; Characteristics of excluded
studies.
Results of the search
We identified no new trials for inclusion in the 2011 update
searches (out of 99 records recovered). The MEDLINE search
in 2009 retrieved 86 publications; the EMBASE search retrieved
308; the Web of Science search 67; and the CENTRAL search
13 publications. From these search results we found three con-
trolled trials which provided data pertinent to the prevention of
pneumonia with vitamin C supplementation and two trials which
provided data on the therapeutic effect of vitamin C.
The main features of the included trials are summarised in the
’Characteristics of included studies’ table. The methods are de-
scribed here in more detail, largely using direct excerpts of the
original papers as these show the strengths and weaknesses of the
trials in the words of the original trial authors.
Included studies
The Glazebrook 1942 trial was the oldest trial identified. The
structure of the paper is quite different from more modern trial
reports: “In a large training school under our observation there
were some 1500 youths aged 15-20 years. For the most part they
were drawn from the lower wage-earning classes . . . The food dis-
tribution [at the school] was badly managed. . . Often 8 hr. elapsed
between the time the food was cooked and its arrival on the dining
tables . . .The total intake of vitamin C varied from about 10 to
15 mg per student per day” (pages 4 to 5). “Pure ascorbic acid
powder was added to . . . the morning cocoa, and an evening glass
of milk. The mixing was done in bulk in the kitchens before issue.
The powder dissolved quickly and easily, and did not alter the
appearance or taste of the vehicle” (page 7). We consider that the
trial corresponds functionally to a placebo-controlled trial because
the participants were unable to identify the treatment, although
no inactive powder was added to the food of the control group.
“The establishment was divided into seven groups or divisions for
administrative purposes. The youths of one division worked as a
unit, and occupied certain tables in the dining hall. To some extent
each division occupied particular dormitories, but this separation
was not absolute, and there was a fair amount of mixing of di-
visions in the sleeping quarters. Sleeping and feeding conditions
were, of course, the same for all divisions. Careful records had
been kept of the incidence of all infections for 1½ years before
the observations described here were begun. In the preceding year
there had been an epidemic of tonsillitis, which had affected all the
divisions uniformly, so that they could not be regarded as separate
units within the larger populations” (page 12). “The observations
were made by supplying vitamin C in the form of pure ascorbic
acid to one or more divisions. This was considered to be the only
practical method of carrying out the observations without intro-
ducing unnecessary complications. For example, it was not possi-
ble to choose boys at random as it would have been impossible to
supply them with vitamin C-treated cocoa or milk in the dining
room. With the method actually chosen, all that was necessary was
to add vitamin C to the supplies of cocoa or milk serving the tables
for the appropriate divisions” (page 12). “Moreover, all of the di-
visions had a population more or less the same as regards duration
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of stay in the establishment (’institution age’). Infectious diseases
were more common amongst those who had more recently joined
the institution” (page 12). “When a youth felt ill he was admit-
ted to Sick Quarters unless his complaint was very mild. . . The
admission to and discharge from the hospital was not under our
control ” (pages 13 to 14). [As to pneumonia:] “These cases were
subjected to special investigations by us (X-rays, etc.) to establish
certain criteria for the diagnosis” (page 16). However, it was not
stated whether the diagnosis of pneumonia was carried out by the
trial authors of the paper or the physicians at the Sick Quarters.
Although the method of diagnosing pneumonia was not described
in detail in the paper, with the given descriptions and the severe
pathological processes occurring in pneumonia it seems unlikely
that vitamin C treatment would have substantially affected the
diagnosis of pneumonia.
Hunt 1994 described that “The patients enrolled into this . . . study
were suffering from acute bronchitis (often acute exacerbation of
chronic bronchitis) or bronchopneumonia. Patients suspected or
known to be suffering from lung cancer were excluded from the
study, as were those who were judged by the clinician to be at
high risk of death within a day or two of admission” (page 213).
Thus the patients were a mixture of bronchitis and pneumonia
patients, whereas in our methods section our purpose was to focus
on pneumonia. However, with the soft clinical definition of pneu-
monia, as discussed in the ’Background’ and ’Types of outcome
measures’ sections and the high false negative proportion in CXR
versus high-resolution computed tomography (HRCT) compari-
son (see above), we included this trial in our analysis. Neverthe-
less, the wider definition of lower respiratory tract infection in this
trial needs to be considered when drawing conclusions. “The pa-
tients were enrolled over a period of three years and were admitted
mainly in the winter months. . . acute respiratory infection had, in
all cases, been the primary reason for hospitalization” (page 213).
“For consistency all clinical assessments were performed by the
same Associate Specialist. Three main diagnostic features of infec-
tive respiratory conditions, namely cough, breathlessness and ra-
diographic evidence of chest infection were used. Each was scored
by the clinician according to severity. . . Then for each person,
at each assessment interval, his or her three main diagnostic fea-
ture scores were added to give the ’total respiratory score’. By this
procedure, the worst score that could be achieved by the most
severely ill patient (whilst still alive) was 9, whilst those who were
completely well with regard to the respiratory condition would
score 3. A score of 10 was given for subjects who died during the
trial. . . Assessments were made on admission (0 weeks) and at
2 and 4 weeks after admission. If patients were discharged from
hospital as ’well’ before 4 weeks, therapy was discontinued and
they were assumed to remain well for up to 4 weeks, for the pur-
pose of clinical scoring (none of the patients discharged were read-
mitted during their 4 week assessment period)” (page 213). “The
clinical score results were approximately normally distributed...”
(page 214), which allowed us to use the t-test in the comparison
of the clinical score values. “After the initial clinical assessment . .
. the patients commenced placebo or vitamin C therapy to which
they were allocated on a randomized ’double-blind’ basis. This
was in addition to their normal medication” (page 213). Thus,
the test of vitamin C effects was “over and above those of normal
medication (mainly antibiotics and cough medicines) to which
all participants were exposed” (page 217). “The vitamin C and
placebo tablets were indistinguishable from each other by look or
taste” (page 213). “None of the subjects who died on the trial had
any secondary diagnosis, including ischaemic heart disease, and
death was attributed directly to respiratory infection in each case”
(page 217). At baseline, the mean plasma vitamin C level was 23.3
µmol/L and 35% patients had a vitamin C level lower than 11.4
µmol/L (page 215). After four weeks, the vitamin C level was 94.9
µmol/L (+307%) in the vitamin C group but only 24.4 µmol/L
(+5%) in the placebo group (page 215).
The Kimbarowski 1967 trial was poorly described. Although pub-
lished in German, an English translation is available. The main
focus of the trial was to examine a chemical test, which is not
relevant to the current review. However, as a secondary issue, in
their report the authors reported the number of bronchopneumo-
nia cases in vitamin C and control groups after hospitalisation.
The trial authors excluded the pneumonia cases from their fur-
ther study (page 2414). For this review the pneumonia cases are
relevant since they occurred after vitamin C supplementation was
initiated. Although the pneumonia cases occurred after hospital-
isation, they occurred within a week and thus did not fall into
the category of nosocomial pneumonia. “The studies were con-
ducted with the use of soldiers almost all of whom were of the
same age and received the same diet . . . The diagnosis of influenza
was based mainly on the clinical pictures and epidemiological data
with serological confirmation in a series of cases involving the type
A virus.” The geographic location where the trial was carried out,
the military institution(s), the hospital in which the trial was car-
ried out and the characteristics of the soldiers were not described.
The allocation method was not described but the study arms were
of closely similar size (112 versus 114 in the control and vitamin C
arms, respectively, before excluding the bronchopneumonia cases)
so it is possible that allocation occurred sequentially to the two
trial arms. The two arms were well-balanced for severity of the
influenza. The number of severe cases was 64 versus 65, moderate
cases 26 versus 32, and mild cases 12 versus 14 in the two arms
respectively (page 2414); the pneumonia cases were not included
in these figures. A placebo was not mentioned in the paper and
apparently was not used. Blinding of outcome assessment was not
described. However, since pneumonia was a secondary issue in the
study, the trial authors did not have reason to compare the num-
ber of pneumonia cases between the trial arms. It seems improb-
able, therefore, that the trial authors had substantial bias in their
diagnosis of pneumonia. CXR (“Röntgenoscopie”) was explicitly
mentioned in the paper as a method that was used. It is probable
that the diagnosis of bronchopneumonia was based on the CXR,
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however, this was not explicitly stated in the paper.
The paper by Mochalkin 1970 is in Russian and a translation into
English is available. The selection criteria for the participants were
not described; neither were many other methodologically relevant
aspects. Placebo was not mentioned and probably was not used
in the control arm. However, participants in two other trial arms
were administered different doses of vitamin C and the lower-dose
arm was used as the reference group in the primary analysis of
this review because it seems unlikely that the difference between
these arms might be explained by the placebo effect. “The group
of patients comprised 140 males diagnosed with acute pneumonia
hospitalised during the first two days of onset of the disease [124
patients were 20 to 60 years of age, and 16 were over 60 years].
Depending on the mode of basic treatment, the patients were di-
vided into three groups: Group I (70 patients) was treated with an-
tibiotics without ascorbic acid (25 patients were treated with peni-
cillin, 15 with streptomycin, 15 with penicillin and streptomycin,
and 15 with tetracycline); Group II (39 patients) was treated with
antibiotics combined with vitamin C (50 mg per 100,000 antibi-
otic units) (15, 8, 8, 8 patients in the antibiotic groups, respec-
tively); Group III (31 patients) was treated with antibiotics com-
bined with ascorbic acid (100 mg per 100,000 antibiotic units)
(10, 7, 7, 7 patients in the antibiotic groups, respectively)” (page
18). Ascorbic acid powder was taken orally. Both antibiotics and
ascorbic acid were used for 10 days . . . All patients were tested un-
der equal conditions of placement, care, and nutrition, and were
subjected to a complex therapy which included antibiotics . . . To
monitor the effectiveness of the employed methods of treatment,
we used the following parameters: dynamics of temperature nor-
malisation, erythrocyte sedimentation rate, leucocyte quantity in
the peripheral blood, timing of wet rattle disappearance, duration
of roentgenologically-determined changes in the lungs, and the
mean period of recovery“ (page 18). At baseline, the mean plasma
vitamin C level was 41 µmol/L. After 10 days treatment, the vi-
tamin C level was 43 µmol/L (+7%) in the higher-dose vitamin
C group but only 23 µmol/L (-44%) in the control group.
The authors of Pitt 1979 were primarily interested in the effect
of vitamin C on the incidence of the common cold. However,
other severe respiratory infections including pneumonia were also
recorded. ”The participants were male marine recruits who under-
went 11 weeks of recruit training at Parris Island, South Carolina
in October to December. . . Pill taking did not begin until the
recruit’s third week at Parris Island“ (page 908). ”These 862 re-
cruits were assigned randomly to either the vitamin C or placebo
group from a list of consecutive numbers randomized in pairs.
Randomisation was carried out by individual recruits within each
platoon“ (page 908). ”Of the 862 recruits who began taking the
pills, 64 recruits (34, vitamin C; 30, placebo) were removed from
their platoons by the US Marine Corps for further training or for
discharge during the eight-week study period. An additional 123
recruits (64: vitamin C; 59: placebo) were excluded from the final
analysis because they did not continue to take their pills for the
eight-week study period. One additional recruit was eliminated
from the vitamin C group because of recurrent urticaria related to
taking the tablets“ (page 909). ”Before the initiation of pill tak-
ing, each recruit received adenovirus 4 and influenza vaccines and
either intramuscular penicillin G benzathine or oral erythromycin
estolate as streptococcal prophylaxis“ (page 908). ”Pill taking was
supervised and observed by the drill instructors in each platoon.
Neither the recruits or drill instructors nor the physicians and
corpsmen who treated the recruits were aware of which pill any
individual was taking“ . . . ”The placebo tablets were formulated
from citric acid and were indistinguishable in appearance and taste
from the vitamin C tablets“ (page 908). ”Pneumonia developed in
eight recruits. . . Each of these eight recruits had typical roentgeno-
graphic and physical signs of pneumonia, although five recruits
were febrile and only four recruits had elevated white blood cell
counts. Pneumococci were isolated from the sputum in three re-
cruits and seen intracellularly on Gram’s stain in two other recruits.
Two of these recruits also had four-fold increases in parainfluenza
titers . . . Each of these recruits returned to his platoon after a
mean Medical Dispensary stay of 4.4 days“ (page 910). Pitt and
Costrini did not estimate dietary vitamin C intake; however, their
participants’ mean vitamin C plasma level was rather high initially,
56 µmol/L (10 mg/L) (page 909), which would correspond to
a dietary intake of 100 mg/day or more (Levine 1996). After six
weeks, the vitamin C level was 77 µmol/L (+36%) in the vita-
min C supplemented group and 52 µmol/L (-7%) in the placebo
group (page 909).
Excluded studies
Five excluded studies are described in the ’Characteristics of
excluded studies’ table. Links to the trial reports and translations
can be found at www.ltdk.helsinki.fi/users/hemila/CP/.
Risk of bias in included studies
Two of the trials were double-blinded, placebo-controlled RCTs
without serious methodological defects and, from the descriptions,
there was appropriate allocation concealment in these double-
blind trials (Hunt 1994; Pitt 1979). Three other trials had method-
ological shortcomings of varying degrees, as described in the pre-
vious section (Glazebrook 1942; Kimbarowski 1967; Mochalkin
1970), and the possible role of these shortcomings in the interpre-
tation of the study results is considered in the Discussion section.
The risk of bias is summarised in Figure 1.
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Figure 1. Risk of bias summary
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Allocation
Pitt 1979 describes that marine recruits were assigned randomly
to the groups from a list of consecutive numbers randomised in
pairs. Randomisation was carried out by individual recruits within
each platoon. Since the study was double-blind, allocation was
concealed. Hunt 1994 describes that patients commenced placebo
or vitamin C therapy to which they were allocated on a ran-
domised double-blind basis, without giving further details. Since
the study was double-blind, allocation was concealed. Glazebrook
1942 allocated schoolboys as administrative units of the boarding
school. Thus, allocation was not concealed for the researchers, but
it may have been concealed for the schoolboys since the researchers
pointed out that vitamin C was added in the kitchen and it did not
alter the appearance or taste of the vehicle (cocoa or milk). The
number of participants in the vitamin C and placebo arms of the
Kimbarowski 1967 was closely equal suggesting alternative alloca-
tion, but this is not explicitly stated. The report does not give any
basis to assume allocation concealment by the researchers, while
no conclusions can be drawn for the participants. Mochalkin 1970
has groups of quite different sizes indicating that it was not ran-
domised. No description is given about the forming of the study
groups.
Blinding
The Pitt 1979 and Hunt 1994 studies were double-blind.
Glazebrook 1942 described that vitamin C was added in the
kitchen and it did not alter the appearance or taste of the vehi-
cle (cocoa or milk), indicating that the participants were blinded
for vitamin C administration (see Included studies). Glazebrook’s
description further indicates that the diagnosis of pneumonia was
made in the Sick Quarter by physicians who were not involved in
the study so that they probably were blinded as to the treatment
group (see Included studies). The level of blinding cannot be con-
cluded for the Kimbarowski 1967 and Mochalkin 1970 trials.
Incomplete outcome data
The Glazebrook 1942 study was carried out in a boarding school
and the report does not indicate that school children might have
dropped out from the trial. Kimbarowski 1967 did not describe
any drop-outs before pneumonia was diagnosed. Pitt 1979 de-
scribed that 64 marine recruits (7.4% of the initial 862) were re-
moved from their platoons and did not continue in the trial, but
there was no difference between the study arms. An additional 123
recruits (14.3% of the initial 862) were excluded from the analysis
because they did take their pills, but there was no difference be-
tween the study arms. One recruit was removed from the vitamin
C group because of adverse effect. Thus, 22% of participants were
not included in analysis, but there was no difference between the
study arms. Hunt 1994 states that four patients were excluded be-
cause of ”incomplete information“ without further details and 57
remained for the analysis; the distribution of the excluded patients
is not described. The Mochalkin 1970 study was carried out in a
hospital in the former Soviet Union. No comment on drop-outs is
given in the report, but it seems unlikely that many patients might
have dropped out from the trial.
Selective reporting
Glazebrook 1942, Kimbarowski 1967 and Pitt 1979 considered
pneumonia either of secondary interest or as a nuisance and there-
fore the findings for pneumonia were not selectively reported be-
cause of the findings. Hunt 1994 was specifically interested in the
treatment of pneumonia and there are no indications in the paper
that the reported outcomes would have been selected from a larger
set. Mochalkin 1970 measured temperature, erythrocyte sedimen-
tation rate, leukocyte level, time of wet rattle disappearance, time
of normalisation of CXR and the mean period of recovery. All
these outcomes were reported.
Other potential sources of bias
See the section Included studies above.
Effects of interventions
Preventing pneumonia
Three trials reported the number of pneumonia cases in vitamin
C and control groups. All these trials found an 80% or greater
decrease in the incidence of pneumonia in the vitamin C group
(Analysis 1.1; Figure 2). Since the number of cases in the vitamin
C groups was very low (zero to two cases in all of the trials) we used
the Peto method for calculating the odds ratio (OR) as an approxi-
mation to the risk ratio (RR). The confidence intervals (CI) in the
three trials were wide and overlapped substantially and there is no
evidence of heterogeneity (Chi2 test (2 df ) = 0.03 and I2 statistic =
0%) . However, the trials were clinically so heterogeneous that we
did not calculate a pooled estimate of effect, because we did not
consider that such a pooled estimate was meaningful. Neverthe-
less, all three trials tested the general question of whether vitamin
C differs from placebo regarding susceptibility to pneumonia.
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Figure 2. The prophylactic effect of vitamin C against pneumonia
The Peto OR method is suitable for calculating an estimate of OR
and its CI. However, with only a few observed cases, the mid-
P value was the more appropriate method to compare the study
groups. In each of the three prophylactic trials, the mid-P value (2-
t) for the comparison of trial arms was below 0.05 and the com-
bined mid-P value (2-t) for the three trials was 0.00004 (Hemilä
1997c), indicating that the differences between the vitamin C and
control arms in these three trials were unlikely to be explained by
random variation.
Subgroup analysis by vitamin C dosage of less or more than 100
mg/day did not reveal any effect of the dose; however, the trials
were clinically so heterogeneous and the number of cases so low so
that we could not make any conclusions about dose-dependency.
All three trials mentioned the usage of the chest radiograph (CXR)
but none of them provided a well-defined case definition of pneu-
monia. Thus we did not carry out a subgroup analysis by use of a
CXR for diagnosis.
We carried out sensitivity analysis in this set of prophylactic trials
by excluding trials that did not use randomisation and placebo.
This left Pitt 1979 as the only trial with high quality methodology.
Nevertheless, the findings of the Pitt 1979 trial did not meaning-
fully differ from the other two trials. As noted above, the trials were
clinically heterogeneous and we do not expect the same treatment
effect in such variable conditions; however, there was no evident
trend for the most positive findings to occur in methodologically
less satisfactory trials.
In the Glazebrook 1942 trial, allocation to treatment groups was
carried out by institute ’divisions’ and not on the basis of individual
boys. Therefore, we also analysed the Glazebrook 1942 trial using
the ’division’ as the unit of observation. Distribution of pneumo-
nia cases in the five control divisions was 5, 3, 2, 4 and 3 (mean
3.4 cases per division) and in the two vitamin C divisions it was
0 and 0. We assumed that the mean of the control divisions was a
suitable estimate for the Poisson distribution mean and used that
assumption as a basis for statistical analysis. The size of the indi-
vidual divisions was not stated in the paper but the two vitamin C
divisions had on average 167 boys (335/2) and the five control di-
visions 220 boys (1100/5), thus the size of the vitamin C divisions
was 0.76 times the size of the control divisions. We adjusted the
mean incidence by this ratio, so that we expected 2.6 pneumonia
cases per vitamin C division, assuming the same incidence as for
the control divisions. With this Poisson mean, we calculated the
probability that there was no case of pneumonia in one vitamin C
division as P value = 0.074 and no case in two separate vitamin C
divisions as having a P value = 0.006. Accordingly, using a ’divi-
sion’ as the unit of observation also revealed a significant difference
between the vitamin C and control groups.
Treating pneumonia
Two trials examined the effect of vitamin C on patients with pneu-
monia (Mochalkin 1970), or pneumonia and bronchitis (Hunt
1994).
Hunt 1994 found 85% lower mortality in the vitamin C group
compared with the placebo group, but this comparison was based
on six cases only (Analysis 2.1). For this difference, the mid-P
value = 0.12. In addition, Hunt examined the change in total
respiratory score at four weeks and these data are presented in
Table 2. There was statistically marginal significance of overall
benefit on the respiratory score with vitamin C, but in a subgroup
analysis based on the baseline severity of disease, the benefit was
restricted to patients who were most severely ill when admitted
to the hospital. These most severely ill patients had substantially
lower vitamin C plasma levels compared with the less ill patients.
In the less ill patients, there was no difference between the trial
arms (Table 2). In their report, Hunt 1994 published the scores
for all participants and for the most severely ill patients; for this
review we calculated the scores for the less ill patients (see Table
2).
Mochalkin 1970 had three trial arms: control, low vitamin C
and high vitamin C. The control arm was not administered a
placebo and, therefore, we restricted our primary analysis to the
comparison of the two vitamin C arms (Analysis 2.2). Their pro-
tocol meant that the mean vitamin C dose of the higher-dose
arm was exactly double that of the lower-dose arm, although the
dosage ranges within both vitamin C arms varied and overlapped
(see ’Characteristics of included studies’). There was a statistically
highly significant decrease in length of hospital stay in the higher
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vitamin C dose arm compared with the lower-dose arm.
As a secondary analysis we present the results of the three arms
of the Mochalkin 1970 trial in Table 1. Mochalkin reported the
proportion of participants with no fever after seven days and with
normalisation of the CXR in 10 days. For both outcomes, the
vitamin C arms fared significantly better than the control arm.
The number needed to treat (NNT) was around five for these two
outcomes compared to the control group (Table 1).
We had planned a subgroup analysis of therapeutic trials by vita-
min C dosage less and more than 1 g/day. Hunt 1994 used only
0.2 g/day. One of the Mochalkin 1970 arms was lower than the
limit, but the other arm had a range over the limit and the planned
subgroup analysis was thus not possible. However, the Mochalkin
1970 results suggest dose-dependency (Table 1). The duration of
recovery was reduced from 23.7 days in the control group by 4.6
days (19%) in the low-dose vitamin C arm and by 8.6 days (36%)
in the high-dose vitamin C arm. Since the mean vitamin C dose
in the high vitamin C arm was exactly twice the mean of the lower
vitamin C arm, the linearity in this response is striking (Table 1).
Sensitivity analysis based on the rejection of trials which were not
randomised, left the Hunt 1994 trial as the only trial with high
quality methodology. Thus, here too there was no evident trend
to suggest that positive findings might be simply explained by
methodological shortcomings of the trials.
Both therapeutic trials used CXR when evaluating patients, but
neither provided a well-defined case definition of pneumonia;
nor of lower respiratory tract infection in the Hunt 1994 trial.
Mochalkin 1970 used normalisation of CXR as one of their out-
comes, which implies that changes in CXR were included in their
criteria to define pneumonia.
D I S C U S S I O N
Summary of main results
We identified three prophylactic trials which recorded 37 cases
of pneumonia in 2335 people and two therapeutic trials involv-
ing 197 pneumonia patients. All of these studies found benefit of
vitamin C. One prophylactic and one therapeutic trial were sat-
isfactorily randomised, double-blind and placebo-controlled and
thus the benefits were not restricted to methodologically less sat-
isfactory trials. However, the five trials were all carried out under
conditions that are far from the ordinary life of people living in
Western countries. Thus, even though the studies suggest a bi-
ological effect of vitamin C, no direct extrapolations should be
made for the general population. None of the trials reported note-
worthy adverse effects of vitamin C, and there is much additional
literature indicating that vitamin C is safe (see section on Safety
below).
Overall completeness and applicability of
evidence
Although we consider that the findings of the analysed pneumonia
trials are reliable, we understand that great caution is required
in the interpretation of the findings because of various biological
factors, for example, vitamin C amounts in the diet and the kind
of participants used in the trials.
Both Pitt 1979 and Kimbarowski 1967 examined soldiers who had
substantially dissimilar living conditions compared with ordinary
adults. Furthermore, Kimbarowski’s soldiers were hospitalised be-
cause of influenza A, making them a very special group of people.
Glazebrook 1942 studied teenage boys in a UK boarding school
during World War II. The age range of Hunt 1994 patients was
from 66 to 94 years, obviously restricting any generalisations to-
wards young people. Mochalkin 1970 included a wide age range
of participants, but their social and nutritional backgrounds were
not described in the paper.
An important feature related to the patient selection in the preven-
tion trials was the very high incidence of pneumonia. Glazebrook
1942 and Pitt 1979 recorded 60 and 120 cases of pneumonia
per 1000 person-years in their control arms, respectively, and
Kimbarowski 1967 reported that 10% of their control arm be-
came sick with pneumonia within one week after hospitalisation.
In contrast, in the ordinary middle-aged Western population, the
incidence of pneumonia is one to three per 1000 person-years
(Baik 2000; Hemilä 2004). Thus, the high incidence of pneumo-
nia makes the conditions of the prevention trials very special and
limits generalisations of their results.
A further issue of great importance is the level of vitamin C intake,
in diet and in supplements. A different outcome between vitamin
C and control arms may result from a very low dietary intake
in the control arm (’marginal vitamin C deficiency’) or from the
high-dose supplementation in the vitamin C arm. In the former
case, a small dosage of supplement might produce a similar effect,
whereas in the latter case the large dose is essential. As reference
levels, scurvy may be caused by vitamin C intakes less than 10 mg/
day, whereas the mean vitamin C intake in the USA is about 100
mg/day (IOM 2000).
Glazebrook 1942 estimated that their participants got only 10 to
15 mg/day of vitamin C in their diet, so that the baseline intake
was close to scurvy levels. Kimbarowski 1967 and Mochalkin 1970
carried out their studies in the former Soviet Union and it seems
highly unlikely that their diet was rich in vitamin C. Hunt 1994
reported overall low plasma levels of vitamin C, and the benefit
of vitamin C was restricted to patients who had particularly low
vitamin C levels (Table 2). Thus, in these trials the benefit of
vitamin C supplementation may be explained by treating ’marginal
vitamin C deficiency’. A similar proposal, emphasising the low
dietary intake levels, was also made to explain the reduction in
common cold incidence in a set of trials with UK males by vitamin
C (Hemilä 1997b).
However, the explanation based on ’marginal deficiency’ is not
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applicable to the Pitt 1979 trial, which reported high baseline
vitamin C levels. In the Pitt trial, the baseline plasma vitamin C
level was 56 µmol/L, which corresponds to a dietary intake of
100 mg/day or more (Levine 1996). In contrast, in the more ill
patients of Hunt 1994 the baseline vitamin C level was only 19.9
µmol/L, and in the Mochalkin 1970 trial plasma vitamin C level
dropped to 23 µmol/L in the control group. Thus, it seems that
low dietary vitamin C intake may not explain the findings in the
Pitt 1979 trial. This trial used the highest vitamin C dose: 2 g/
day. Participants of the Pitt 1979 trial were marine recruits in a
training camp, that is under particularly stressful conditions. It is
also worth noting that vitamin E, a lipid-soluble antioxidant which
interacts with vitamin C, reduced the incidence of pneumonia by
half in male smokers who carried out leisurely exercise (Hemilä
2006b) and vitamin C reduced the risk of common cold in six
trials with participants under heavy acute physical stress (Hemilä
1996; Hemilä 2010). Thus, it is possible that the particularly hard
training of the military recruits of the Pitt 1979 trial is the reason
why the high-dose vitamin C supplementation was beneficial for
some of their participants.
The explanation of ’marginal deficiency’ is also not applicable to
the comparison of the two vitamin C arms of the Mochalkin 1970
trial. Although the Hunt 1994 trial found a benefit of vitamin C
supplementation only in the most ill patients who concurrently
had low plasma vitamin C levels (Table 2), the Mochalkin 1970
trial found dose-dependency, indicating that the therapeutic effect
of vitamin C supplementation was not limited to treating ’marginal
deficiency’ (Table 1). An indication of dose-dependency up to 6
g/day of vitamin C was also found in a common cold trial by
Karlowski 1975 (see also Hemilä 1996; Hemilä 2006a).
Hunt 1994 combined the cases of acute bronchitis and pneumo-
nia together. In young people, acute bronchitis usually has a vi-
ral aetiology, whereas the majority of pneumonia cases are caused
by bacteria. However, Hunt 1994 patients were all over 60 years
of age and their acute bronchitis was ”often acute exacerbation
of chronic bronchitis“, implying bacterial aetiology. The clinical
definition of pneumonia is soft and chest X-ray (CXR) has a sub-
stantial proportion of false negatives. For such reasons the com-
bined outcome used in the Hunt 1994 trial was appropriate in the
current review.
Quality of the evidence
We identified three trials that reported on the preventive effect of
vitamin C against pneumonia, and two trials that reported on the
therapeutic effect of vitamin C on patients with pneumonia. Each
of these trials found a statistically significant benefit of vitamin C
supplementation on at least one clinically relevant outcome. Two
of the trials were placebo-controlled, randomised trials, whereas
the other three trials were technically deficient to varying degrees.
Here we considered whether potential biases could explain the
differences between the vitamin C and control groups.
The concept of publication bias is based on an assumption that
researchers tend to report a study if the result is ’positive’ and tend
to leave it unreported if the result is ’negative’. With this reasoning,
it might be possible that the five trials analysed in this review
were published just because of the significant benefit of vitamin
C, whereas there might be several trials unpublished because of
their negative results. However, the three papers reporting on the
prophylactic effect of vitamin C were published separate to the
effect of vitamin C on pneumonia; the benefit on pneumonia not
being the motive for publication. Glazebrook 1942 was mainly
interested in the common cold and tonsillitis and the effect on
pneumonia was mentioned as a secondary issue, indicating that
this finding was not the reason for publication. Kimbarowski 1967
considered pneumonia as a nuisance in their trial as they focused on
a chemical test. They did not pay any attention to the substantial
difference in the occurrence of pneumonia in the trial arms and,
for example, in their summary the pneumonia cases in both trial
arms were combined. Pitt 1979 focused on the common cold,
and pneumonia was a secondary outcome which was reported
in the text but not in the abstract. Thus these three reports are
inconsistent with publication bias as an explanation for the set of
positive reports. This explanation with regard to the background
of the investigators is also relevant when considering detection bias
(see below).
In the case of the therapeutic trials by Hunt and Mochalkin, there
were biological consistencies which are not easily explained by
pure chance. Hunt 1994 found that the benefit was limited to
the patients with the lowest vitamin C levels, which is biologi-
cally reasonable (Table 2). Mochalkin 1970 found a linear dose-
response relation in the two vitamin C arms compared with the
control group (Table 1). Neither Hunt nor Mochalkin paid proper
attention to these findings and thus they were not likely to be the
basis for publication. Furthermore, speculation on a large number
of unpublished trials to explain positive reported findings is not
science in the Popperian sense as such a hypothesis cannot be re-
futed. Thus, we do not consider publication bias as a reasonable
explanation for the reported positive findings in the published
prophylactic and therapeutic trials.
Selection bias means that there are systematic differences in the
compared groups at baseline. In therapeutic trials, the severity of
disease is a factor of obvious importance. The Hunt 1994 trial
was randomised and allocation was concealed. The distribution
of ’acute bronchitis’ and ’bronchopneumonia’ and the proportion
of ’most severely ill’ were closely similar in the treatment arms.
Mochalkin 1970 did not describe the distribution of pneumonia
severity, but antibiotic treatments were distributed evenly in the
three arms, so that if the selection of antibiotics depended on the
clinical symptoms they were also divided evenly.
In prophylactic trials, there is a lower possibility of bias caused by
baseline differences between the treatment arms. Maldistribution
of a strong risk factor, such as smoking in a study of lung cancer,
may however lead to erroneous conclusions. Cohort studies have
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not identified strong risk factors for community-acquired pneu-
monia, with the age of the person being most important (Baik
2000; Hemilä 2004). Thus, to explain an 80% or greater reduction
in the incidence of pneumonia in the vitamin C arms (Analysis 1.1)
would require that there is a strong risk factor that is spectacularly
maldistributed. Furthermore, the Pitt 1979 trial was randomised
and double-blind, and Glazebrook 1942 used pre-formed divi-
sions and explicitly considered that the groups of schoolboys were
similar. In the Kimbarowski 1967 trial, the severity of influenza
probably was the most important risk factor for the occurrence of
pneumonia, but it was distributed evenly in the trial arms. Thus,
it seems unlikely that systematic baseline differences between the
trial arms would explain the benefits observed in the vitamin C
arms.
Performance bias means systematic differences in the care pro-
vided, apart from the intervention being evaluated. The Hunt
1994 and Pitt 1979 trials were double-blinded. According to the
Glazebrook 1942 description, the boys in different divisions were
treated equally. Kimbarowski 1967 stated that the participants re-
ceived the same diet, but otherwise the similarity of other treat-
ments was not mentioned. Mochalkin 1970 stated that all patients
were tested under equal conditions of placement, care and nutri-
tion and the use of antibiotics was similar in the treatment arms.
Although Mochalkin did not use a placebo in the control group,
the placebo effect does not explain the difference between the two
vitamin C arms (Analysis 2.2 and Table 1). Furthermore, with
the significant difference in the duration of pneumonia in the two
vitamin C groups, it is not reasonable to assume that the differ-
ence between the control group and the low-dose vitamin C group
might be caused by the placebo effect alone. Such an explanation
would presuppose that there is a threshold dose so that vitamin C
has no effects at lower doses; only at higher doses. Such a dose-
response model would be opposite to the findings of many studies
indicating that the benefits are more pronounced in the low-dose
region (see below comments on ’marginal vitamin C deficiency’).
Thus, in two trials there was good evidence that participants were
treated equally, except for the vitamin C supplementation, and
in the other trials there was no explicit reason to assume that the
other treatments would substantially differ between the trial arms.
Attrition bias means high or divergent drop-out proportions and
does not seem to be a substantial concern in these five trials. The
three trials examining the preventive effect of vitamin C were car-
ried out within military organisations or in a boarding school.
The background and descriptions in the papers did not suggest a
considerable drop-out problem. Pitt 1979 stated that 22% of the
initial population were removed from their platoons or did not
continue to take their pills, and were not included in the final anal-
ysis, but the drop-outs were distributed evenly in the treatment
arms. Hunt 1994 followed up the patients for four weeks and did
not report any drop-outs. Mochalkin 1970 did not comment on
drop-outs, but the distribution of antibiotic usage was even in the
trial arms, which would seem to exclude any drop-outs.
Detection bias means systematic differences in outcome assess-
ment. The Hunt 1994 and Pitt 1979 trials were double-blinded
and, therefore, bias caused by the knowledge of participants or in-
vestigators was unlikely to have affected the outcome assessment.
As noted above, in the Glazebrook 1942, Kimbarowski 1967 and
Pitt 1979 trials, pneumonia was a secondary issue and it is un-
likely that under such conditions the investigators would have any
tendency to diagnose pneumonia differently in the trial arms. The
Mochalkin 1970 report did not allow any direct or indirect con-
clusions on the possibility of detection bias.
Thus, two of the pneumonia trials were placebo-controlled, dou-
ble-blind randomised controlled trials. Even though the three
other trials were methodologically less satisfactory in comparison
with modern trial standards, the positive findings of these latter
three trials are not easily explained by biases.
Potential biases in the review process
Our search of databases for trials meeting the criteria for our review
was exhaustive but we also read reference lists of several reviews,
such as Briggs 1984, which contained 413 references to papers
related to vitamin C and infections. Although there might be some
unpublished trials or trials published in very difficult to reach
journals or books, it seems unlikely that we could have missed
major controlled trials.
Agreements and disagreements with other
studies or reviews
Although the proponents of evidence-based medicine argue that
”if you find that the study was not randomised, we’d suggest that
you stop reading it and go on to the next article“ (Sackett 1997)
we consider that cohort studies can give an important perspective
to the possible prophylactic effects of higher vitamin C intake.
A recent cohort study found no association between vitamin C in-
take and community-acquired pneumonia in middle-aged men in
the USA (Merchant 2004). There are, however, substantial differ-
ences between this cohort study and the three prophylactic trials
of the Analysis 1.1. Merchant 2004 investigated male US health
professionals of 40 to 75 years of age, the selection of which meant
a population with a much greater than average interest in fac-
tors that affect health and whose working conditions are quite
sedentary. In Merchant’s cohort, the median vitamin C intake of
the lowest quintile was 95 mg/day (overall median 218 mg/day),
whereas the overall median of the ordinary US population is about
100 mg/day (IOM 2000). Thus the range of vitamin C intake in
Merchant’s cohort was substantially higher than in the three pro-
phylactic trials analysed in this review, and the living conditions
were very different compared with the three trials. Furthermore,
Merchant 2004 recorded three pneumonia cases per 1000 person-
years. Thus, even though the Merchant cohort study indicated
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that the level of vitamin C intake did not affect the risk of pneumo-
nia in sedentary, health-conscious, middle-aged populations when
the intake range started from 100 mg/day, their findings cannot
be extrapolated to substantially different population groups such
as those in the trials analysed in the current review. Nevertheless,
the Merchant cohort study gives certain explicit limits to puta-
tive generalisations of the analysed trials. Thus, we consider that
biological differences, rather than methodological differences, are
the most appropriate explanations for the divergence in the role
of vitamin C in the Merchant cohort study and the intervention
trials in Analysis 1.1.
Also, some further trials are relevant to the current topic. Dahlberg
1944 reported respiratory infections more severe than the common
cold in military recruits (five in the vitamin C, 10 in the control
group of the same size; RR 0.5; 95% CI 0.2 to 1.5), but their
outcome included otitis and sinusitis and not just lower respiratory
infections. Nathens 2002 reported that in critically ill surgical
patients vitamin C and E combination had no effect on pneumonia
risk (RR 0.79; 95% CI 0.53 to 1.20); however, patients in the
vitamin C and E group required 0.9 days (95% CI 0.6 to 1.2
days) less mechanical ventilatory support and had a 1.2 day (95%
CI 0.81 to 1.5 days) reduction in their intensive care unit (ICU)
length of stay, indicating benefits of antioxidant supplementation.
However, the role of vitamin C per se is ambiguous and the benefit
was for an outcome not directly linked to infection, even though
a longer ICU stay is associated with a greater risk of pneumonia.
Mahalanabis 2006 reported that 400 mg vitamin E and 200 mg
vitamin C per day had no therapeutic effect on 2 to 35-month old
children with severe acute lower respiratory infection; however,
the vitamin E dose was very high for children of this age and the
study did not allow any specific conclusions on the possible role
of vitamin C.
Safety of vitamin C
Pitt 1979 administered 2 g/day of vitamin C to 331 participants
for two months. None of the reported symptoms that participants
thought to be caused by the pills were statistically more frequent
in the vitamin C than in the placebo arm. Urticaria developed in
one recruit in the vitamin C arm which subsided when the pills
were withheld and recurred when he resumed taking his pills. He
was instructed to stop taking pills and was excluded from the final
analysis. The other trials used lower vitamin C doses and were
much less informative on the safety of high doses.
In general, vitamin C is considered safe in doses up to several
grams per day and although there have been speculations of poten-
tial harms of large doses they have been shown to be unfounded
(Hathcock 2005; Hemilä 2006a). For example, in a recent phar-
macokinetic study, participants were administered up to 100 g of
vitamin C intravenously within a few hours without any reported
adverse effects, indicating the safety of such a large dose in healthy
people (Padayatty 2004). Cathcart 1981 reported that he had ad-
ministered orally over 100 g per day of vitamin C to pneumonia
patients, which indicated safety of such high doses for pneumo-
nia patients, although such an uncontrolled observation does not
provide evidence of benefit. There are few reports of severe harm
caused by high-dose vitamin C administration and the death of
a 68-year old African American man was not attributed to intra-
venous injection of 80 g of vitamin C on two consecutive days per
se, but to his coincident glucose-6-phosphate dehydrogenase (G-
6-PD) deficiency (Campbell 1975).
Mechanism of effect
Our review is largely based on the concept that vitamin C affects
the immune system and thereby protects against infections in an-
imals (Hemilä 2006a). Such effects on the immune system are
plausible explanations for the benefits observed in the prophylac-
tic trials (Analysis 1.1). However, vitamin C also has non-immune
effects that might be relevant in therapeutic trials.
Vitamin C participates in the synthesis of norepinephrine and
a series of neuropeptides (Rice 2000) and carnitine which par-
ticipates in energy metabolism (Hughes 1988; Jones 1982). In a
study of experimentally-induced vitamin C deficiency, Kinsman
1971 compared the state with high and low levels of vitamin C in
whole blood, 93 µmol/L and 25 µmol/L, and found that ”scores
in the neurotic triad of the Minnesota Multiphasic Personality
Inventory (the hypochondriasis, depression and hysteria scales)
became elevated as deficiency of vitamin C progressed“. There-
fore, it is possible that in a therapeutic setting the effects of vita-
min C supplementation are not limited to the immune system.
Vitamin C levels in whole blood are higher than plasma levels,
and thus Kinsman’s levels cannot be directly compared with the
low plasma levels reported by Hunt 1994 and Mochalkin 1970.
Still, low vitamin C levels might cause psychological symptoms,
for which vitamin C supplementation might be beneficial. Some
of the early case reports of pneumonia patients described particu-
larly rapid benefits of vitamin C (Bohnholtzer 1937; Dalton 1962;
Hochwald 1937; Klenner 1948) and such rapid benefits might be
caused by non-immunological effects of vitamin C, rather than
by immunological mechanisms. Consistent with the concept that
vitamin C might have an influence on general well-being, a recent
study reported that vitamin C administration improved the mood
of acutely hospitalised patients (Zhang 2011). It is noteworthy
that in the Mochalkin 1970 trial the vitamin C level dropped by
44% in 10 days in the control group (Table 1), consistent with
other studies that have found reductions in vitamin C levels with
infections (Hemilä 2006a). Neither Hunt 1994 nor Mochalkin
1970 measured any index of general well-being or psychological
status.
Conclusions
15Vitamin C for preventing and treating pneumonia (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
The incidence of pneumonia is low in the middle-aged in the
Western countries; one to three per 1000 person-years (Baik 2000;
Hemilä 2004) and there is no rationale to study the prophylactic
effect of vitamin C in such a population. Even if vitamin C did
have an effect, the low baseline incidence would lead to very high
number needed to treat (NNT) values. Also, the Merchant 2004
cohort study suggests that vitamin C intake level has no association
with pneumonia risk in well-nourished, middle-aged people.
Certain populations have a high risk of pneumonia. In low-in-
come countries the incidence of lower respiratory tract infection in
children has, at the upper extreme, been over 1000 cases per 1000
person-years (Selwyn 1990). Also, in many low-income countries
prevalence of malnutrition is high, indicating low vitamin C in-
takes. Another population group with an elevated risk of pneumo-
nia is elderly people, since the incidence increases with age (Baik
2000; Hemilä 2004). A further population group with high risk
of pneumonia is military recruits; the average incidence of pneu-
monia in marine and naval recruits in the 1970s was 60 per 1000
person-years in a US study (Pazzaglia 1983).
The prophylactic effects of vitamin C should be investigated in
such populations with a high incidence of pneumonia. Even if
the benefit of vitamin C was substantially lower than in the three
prophylactic trials analysed in this review, the effect might still
be important. For example, with a baseline pneumonia incidence
of 60 per 1000 person years, a reduction of risk by half would
correspond to a NNT of 33 over one year of such high risk.
In the USA, pneumonia is the sixth most common cause of death
and the most common cause of infection-related mortality, reflect-
ing its importance (Donowitz 2005). Various infections lead to
decreased vitamin C levels in plasma, leucocytes and urine, sug-
gesting that vitamin C supplementation might have therapeutic
effects on patients with infections (Hemilä 2006a). In addition,
numerous animal studies found that vitamin C supplementation
reduced mortality and morbidity caused by infections (Hemilä
2006a). With this background, the two published therapeutic tri-
als analysed in this review seem particularly important as they indi-
cate that vitamin C supplementation might be beneficial for some
groups of pneumonia patients. Furthermore, even if the benefit
of vitamin C supplementation was limited to specific groups of
patients, such as those with low vitamin C levels, the effect may
be of wide interest given the common occurrence of this severe
infection.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Vitamin C is relatively cheap and it is safe in doses of grams per
day. Nevertheless, with the current evidence there is no basis for
the prophylactic use of vitamin C to prevent pneumonia, because
it would require continuous supplementation with poorly under-
stood effects.
While waiting for new trials, therapeutic vitamin C supplemen-
tation may be reasonable for patients with pneumonia who have
low vitamin C plasma levels, since therapeutic administration is
limited in time. With the low price of vitamin C, the cost-benefit
ratio may be reasonable even if the benefit might be substantially
lower than that observed in the therapeutic trials analysed in this
review.
Implications for research
The prophylactic use of vitamin C to prevent pneumonia should
be investigated in populations who have a high incidence of pneu-
monia, in particular if the dietary vitamin C intake is low. This
means, for example, children in low-income countries, military
recruits and elderly people. In ordinary middle-aged Western pop-
ulations, there is no rationale to study the prophylactic effects of
vitamin C.
The study of the therapeutic effects of vitamin C on pneumonia
patients is well-justified, in particular in patients with low vitamin
C plasma levels but possibly also in participants with ordinary
plasma vitamin C levels. The outcomes of therapeutic trials should
include soft outcomes measuring well-being because vitamin C
may also have non-immune effects, especially in participants with
very low plasma vitamin C levels and pneumonia leads to a sub-
stantial reduction in vitamin C levels.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Glazebrook 1942
Methods Allocation in groups
Quasi-placebo control, see text
Carried out in winter, duration 6 months
Participants 1435 schoolboys in a boarding school in the UK
335 boys in vitamin C divisions (n = 2) and 1100 in control divisions (n = 5)
Age range 15 to 20, mean 16 years
Interventions Vitamin C 0.05 to 0.3 g/day added to the food in the kitchen
Outcomes Incidence of pneumonia
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Treatment groups were based on adminis-
trative divisions of boarding school, no al-
location on individual level
Allocation concealment (selection bias) High risk Concluding from the report, allocation was
not concealed from the researchers, but
may have been from the school boys, al-
though this is not explicitly stated
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Concluding from the report, the partici-
pants were blinded to vitamin C adminis-
tration (see Included studies for details)
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Concluding from the report, the diagno-
sis of pneumonia was made in the Sick
Quarter by physicians who were not in-
volved in the study so that they probably
were blinded to the treatment group (see
Included studies for details)
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Hunt 1994
Methods Randomised, placebo-controlled, double-blind trial
Carried out in October to December
Participants 57 elderly patients: 27 males, 30 females, age range 66 to 94, mean 81 years (28 vitamin
C; 29 placebo)
Hospitalised for acute bronchitis (n = 40) or pneumonia (n = 17)
Interventions Vitamin C 0.2 g/day
Treatment for up to 4 weeks after hospitalisation
Outcomes Mortality




Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Reported as randomised, but no details of
randomisation are described
Allocation concealment (selection bias) Low risk Study was double-blind so that neither par-
ticipants nor researchers knew to which
group the participant had been allocated
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Double-blind trial
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double-blind trial
Kimbarowski 1967
Methods Allocation method not described, but study arms were of similar size (112 and 114
initially)
Placebo not used
Blinding of outcome assessment not described, see text
Groups were balanced on the basis of disease severity at baseline, see text
Participants 226 soldiers hospitalised for influenza A (114 vitamin C; 112 control)
Interventions Vitamin C 0.3 g/day
Outcomes Incidence of bronchopneumonia after hospitalisation
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Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk Concluding from the report, probably
not randomised, but possibly groups were
formed by alternative allocation (114 ver-
sus 112) though this is not explicitly stated
Allocation concealment (selection bias) High risk Concluding from the report, there is no
reason to assume that allocation was con-
cealed
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Concluding from the report, there is no rea-
son to assume that researchers were blinded
to the intervention
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Concluding from the report, there is no rea-
son to assume that researchers were blinded
when assessing pneumonia
Mochalkin 1970
Methods Allocation method not described
Quasi-placebo control, see text
Antibiotic treatments were balanced in study groups
Participants 70 in control group, 39 in low vitamin C group and 31 in high vitamin C group
Interventions High vitamin C: vitamin C 2 mg per 2000 antibiotic units
(vitamin C range: 0.5 to 1.6 g/day)
Low vitamin C (used as placebo group in the primary comparison): vitamin C 1 mg per
2000 antibiotic units
(vitamin C range: 0.25 to 0.8 g/day)
Outcomes Period of recovery
Duration of fever
Duration of chest X-ray normalisation
Notes Control group was not administered placebo and thus the primary analysis focuses on
the high and low vitamin C groups
Risk of bias
Bias Authors’ judgement Support for judgement
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Mochalkin 1970 (Continued)
Random sequence generation (selection
bias)
High risk Randomisation not described and groups
are of such different sizes that it is unlikely
they originate from randomisation
Allocation concealment (selection bias) High risk Concluding from the report, there is no
reason to assume that allocation was con-
cealed
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Concluding from the report, there is no rea-
son to assume that researchers were blinded
to the intervention
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Concluding from the report, there is no rea-
son to assume that researchers were blinded
when assessing pneumonia
Pitt 1979
Methods Randomised, placebo-controlled, double-blind trial
Carried out in October to December, 8-week trial
Participants 674 marine recruits in a training camp in the USA (331 vitamin C; 343 placebo)
Interventions Vitamin C 2 g/day
Outcomes Incidence of pneumonia
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Participants were assigned randomly to the
groups from a list of consecutive numbers
randomised in pairs
Allocation concealment (selection bias) Low risk Study was double-blind so that neither par-
ticipants nor researchers knew to which
group the participant had been allocated
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n = number
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Dahlberg 1944 Military recruits in Sweden. 50 mg/day of vitamin C. The outcome is a mixture of tonsillitis, otitis, sinusitis,
bronchitis and pneumonia making the trial potentially relevant. However, the cases of pneumonia or lower
respiratory tract infection cannot be inferred from the outcome containing also upper respiratory infections
Hunt 1984 One group of diagnoses in the hospitalised patients was ”respiratory infections“ but it was not separated into
lower and upper respiratory infections
Kahn 2011 The study recorded the frequency of pneumonia in burn patients. The abstract suggests that it was a controlled
trial: ”patients were divided into two groups“, one of which was administered i.v. vitamin C. However, the
text indicates that the study was not a trial, but an analysis of a cohort of patients admitted to burn care unit
Mahalanabis 2006a Combination of vitamins C (200 mg/d) and E (200 mg/d) was used for 6 d. Children aged 1 to 10 y with
measles and associated pneumonia; all were clinically diagnosed to have pneumonia. No difference in recovery
rate between treatment (n = 36) and placebo groups (n = 35)
Mahalanabis 2006b Combination of vitamins C (200 mg/d) and E (400 mg/d) was used for 5 d. Children aged 2 to 35 months
with severe acute lower respiratory tract infection. No difference in recovery rate between treatment (n = 89)
and placebo groups (n = 85)
Mochalkin 1975 No placebo in the control group. Benefit was reported in the vitamin C versus no treatment comparison
Nathens 2002 Combination of vitamins C (1000 mg/d) i.v. and vitamin E (1000 IU/d) per naso-orogastric tube for up to
28 d. No difference in the incidence of pneumonia, but significant decrease in the duration of mechanical
ventilation and ICU length of stay
Scheunert 1949 Different doses of vitamin C were administered to several study groups (range 20 to 300 mg/day) so that the
lowest dose arm might be used as the control group.
”Lung disease“ was used as one of the outcomes making the trial potentially relevant
The data are, however, presented so ambiguously that no data could be extracted to this review
Wahed 2008 The description of methods of the 7-arm trial is minimal. The dose of vitamin C is not described. It is not
clear whether a placebo was used. The authors describe that ”initially data was collected from 1150 children
and after exclusions only 800 children were selected for analysis.“ However, the original number of children
in each of the 7 groups is not reported. When the reasons for exclusion seem to be random (complications of
pneumonia etc) it does not seem possible that random dropping out would lead to 5 groups which each had
exactly 40 children and a placebo group which had exactly 400 children. The duration of hospital stay because
of pneumonia in the control group (400 children) was 7.75 days and in the vitamin C group (40 children)
was 7.00 days. However, the SD is not given for the estimates. Due to these and many further problems we
excluded the trial
25Vitamin C for preventing and treating pneumonia (Review)
Copyright © 2011 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
d = days
ICU = intensive care unit
i.v. = intravenous
n = number
SD = standard deviation
y = years
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